Its important to consult your healthcare provider before discontinuing any medication, as they can help you plan for a smooth transition and support ongoing weight management
Certificate of Analysis provided with every order when available
Food and Drug Administration (FDA) prescribing information, Centers for Disease Control and Prevention (CDC) data, and peer-reviewed research from the National Library of Medicine (PubMed), but individual responses may vary
The real question is not whether to offer access
Semaglutide: Promotes weight loss by reducing appetite and caloric intake via GLP-1 receptor activation Trevogrumab: Blocks myostatin, a protein that limits muscle growth, thereby promoting muscle mass increase Garetosmab: Inhibits activin A, AB, and AC, which are also negative regulators of muscle mass, further supporting muscle growth and fat reduction Clinical Trial Findings Phase 2 COURAGE Trial Design: Randomized, double-blind, with multiple arms including semaglutide alone, semaglutide plus trevogrumab (high/low dose), and semaglutide plus trevogrumab and garetosmab
